Pain
Material review, reconciliation, monitoring or oversight friction.
For Pharma & BiotechStudy oversight with
Study oversight with
evidence behind the signal.
WHPL targets selective clinical-development use cases where review burden, fragmented systems, risk visibility or study-control urgency are material enough to justify a focused diagnostic and controlled pilot.
Discuss a Study-Control Use Case →CLINICAL DEVELOPMENT · PORTFOLIO OVERSIGHT
SELECTIVEStudy ControlEvidence behind the signal
Study 01Review burden
Study 02Risk cluster
Study 03Readiness
ReviewRiskOversight
Selective qualification
Not every sponsor workflow should become an opportunity.
Advance where pain, urgency, landscape and an evidence path are real—not because the account is large.
Urgency
A study milestone, leadership initiative, scale pressure or failed status quo.
Landscape
Known systems, integration constraints, alternatives and internal process.
Evidence
A bounded diagnostic or pilot with credible before/after measurement.
Likely Aegis Agents entry points
Use intelligence where expert attention is scarce.
Prioritize what needs expert review across fragmented study signals.
Bring relevant risk indicators into a more controlled evidence and review path.
Make outstanding review, reconciliation and ownership more visible before the lock window.
Next step
Discuss Study Control →Define one sponsor use case that can be proven.
WHPL will focus on the workflow, current systems, economic burden and evidence needed to justify deployment.